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by LDL-C but treated to both LDL-C and LPL-P recommended goals. Results: In 
the general population, the costs per quality-adjusted life year (QALY) associated 
with the use of LDL-P alone were $76,052 at 5 years and $8,913 at 20 years and 
with the use of both markers were $142,825 at 5 years and $25,505 at 20 years. 
In high-risk subpopulations, the use of LDL-P alone was cost-saving at 5 years; 
whereas the cost per QALY for the use of both markers was $14,250 at 5 years and 
$859 at 20 years for high-risk dyslipidemics, $19,192 at 5 years and $649 at 20 years 
for diabetics, and $9,030 at 5 years and $7,268 at 20 years for patients with prior 
CHD. ConClusions: Utilizing LDL-P to guide statin therapy is cost-effective in 
the long term for the general population, and cost-saving or cost-effective in the 
short term for high-risk patients.
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objeCtives: The aim of this study was to evaluate the long-term cost effectiveness 
of ticagrelor + aspirin versus clopidogrel + aspirin in patients with acute coronary 
syndrome (ACS) treated for 12 months in Spain. Methods: The cost effective-
ness model consisted of a decision tree (1st year) based on the PLATO study and 
a long-term Markov model (2nd year onwards). This allowed estimation of cardio-
vascular events (death, myocardial infarction and non-fatal stroke), survival, health 
costs, and health related quality of life. A life time horizon was applied. The daily 
drug cost was € 0.60 and € 2.96 for generic clopidogrel and ticagrelor, respectively. 
Spanish unit costs and life tables were used; outcomes and costs were discounted 
at 3%. A sensitivity analysis across subgroups was carried out, and probabilistic 
sensitivity analysis was used to validate the robustness of the model. Results: 
Ticagrelor compared to clopidogrel was associated with a gain of 0.1586 life years 
and 0.1363 years of quality-adjusted life years (QALY), with an incremental cost of € 
596. The incremental cost per life year and per QALY gained was € 3,760 and € 4,374, 
respectively. The probabilistic sensitivity analysis showed that ticagrelor was cost-
effective versus clopidogrel in > 99 % of the simulations given a willingness-to-pay 
threshold of € 15,000/QALY. The results were consistent across different subgroups 
of ACS patients. ConClusions: Ticagrelor + aspirin for 12 months is a cost effective 
treatment compared to generic clopidogrel + aspirin in patients with ACS treated 
invasively or conservatively, based on the findings of the PLATO study and Spanish 
health care costs.
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objeCtives: This study was conducted to determine the cost-effectiveness of 
carotid Artery stenting (CAS) versus carotid endarterectomy (CEA) in patients with 
symptomatic carotid stenosis (more than 50% stenosis) in Korean health care sys-
tem perspective. Methods: We performed a cost-utility analysis. Costs were esti-
mated from retrospective chart review (CAS= 346, CEA= 331), health insurance claims 
data, and other national resources and expressed in 2013 KRW. Transition probabili-
ties were estimated from retrospective chart and systematic review. Health utility 
index was assessed for general population using Time Trade Off (TTO) with health 
scenario. We used a Markov model to project 15-year costs and quality-adjusted 
life years (QALYs) for the 2 treatment groups. Results: In the base case analysis, 
CAS produced 6.49 QALYs, compared with 6.71 QALYs for CEA. The incremental 
cost of stenting was 1,691,740 KRW. In the base case analysis, CEA for patients 
with symptomatic stenosis had a greater benefit than CAS, with lower costs. In 
subgroup for patients with stenosis more than 70% or patient with over 80 years 
old, CAS was cost-effective. Sensitivity analyses showed that the major stroke or 
mortality influenced the results. However the results were consistent with the base 
analysis. ConClusions: Under the current circumstances in Korea, CEA was domi-
nated by CEA in symptomatic steonsis. Therefore we concluded that CEA would be 
cost-effective intervention for carotid stenosis. To be economically competitive, the 
clinical effectiveness such as mortality and major stroke rates of CAS must be at 
least equivalent if not less than those of CEA.
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objeCtives: To estimate productivity loss and associated indirect costs in working-
age patients treated for hyperlipidemia. Methods: A retrospective population-
based cohort study was conducted using Swedish electronic medical records 
linked to national health registers and the Social Insurance Register. Patients were 
included based on a prescription of lipid-lowering therapy between January 1,2006 
and December 31,2011 and followed until December 31,2012 for estimation of pro-
ductivity loss and cost outcomes. Patients were stratified into three cohorts based 
on cardiovascular (CV) risk level. Results: Total mean days lost, measured as the 
sum of net sick leave and net disability pension days, during the one-year period 
following study inclusion was highest in the CV event history cohort (n= 6,881; 159 
days), followed by the CV risk equivalent (RE) cohort (n= 3,226; 131 days) and the low/
cost savings at 3 years is estimated to be 11.671€ per patient. ConClusions: The 
use of the GORE® PROPATEN® Vascular Graft for infrapopliteal bypass in the PAD 
patient population represents a safe, clinically effective, and cost-saving alternative 
to standard ePTFE vascular grafts.
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objeCtives: Pharmacoeconomic analysis of rosuvastatin use in patients with 
hypercholesterolemia in the health care of Belarus has been performed to deter-
mine economic advisability of its applying in Belarus. As there is own production 
of statins (generics of lovastatin, atorvastatin and simvastatin) in Belarus, the 
insclusion of new statin (rosuvastatin) in the clinical protocols requires pharma-
coeconomic study. Methods: Overview of statins available in Belarus has been 
conducted. Equivalent effective dose to achieve target of low density lipoprotein 
cholesterol (CH-LPLD) values were established on the basis of published data. Cost-
minimization analysis has been used. Model “decision tree” to achieve the target 
CH-LPLD values has been built on the basis of STELLAR trial. Statin doses required 
to achieve the target CH-LPLD values have been calculated. The costs of achieving 
the target CH-LPLD values have been evaluated. The cost of each statins treating 
during the year has been calculated. Results: The highest cost has been obtained 
for the equivalent dose of lovastatin ($ 0.35) compared with atorvastatin ($ 0.31) and 
simvastatin ($ 0.28) manufactured in Belarus. Average price rosuvastatin (Merten 
®) was comparable to the cost ($ 0.21) of Belarusian generics. The average cost of 
achieving the target CH-LPLD level was the lowest in the case of rosuvastatin - $ 170 
compared with atorvastatin ($ 200) and simvastatin ($ 286) considering available 
statins of all manufacturers. Due to rosuvastatin’s lower effective dosage the costs 
of the one-year treatment with rosuvastatin is lower (on average 94 $) than with 
atorvastatin (all manufacturers - $ 100) and simvastatin (202 $). ConClusions: 
The study has demonstrated pharmacoeconomic acceptability of rosuvastatin use 
in the health care of Belarus.
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objeCtives: To assess cost-effectiveness of indapamide 1.5 mg +amlodipine 5/10 
mg single-pill combination (SPC) compared with free combination (FC), in the 
Polish setting. Methods: A Markov cohort simulation model was used. Results 
of meta-analysis by Gupta et al show a difference in patients’ compliance between 
SPC and FC. Better compliance results in lower systolic blood pressure, which 
influences risk of cardiovascular events. Hence, compliance is associated with 
life expectancy and quality of life. Cardiovascular disease risks were based on 
the Framingham risk equations. Life-time horizon, Polish public payer perspec-
tive and patient perspective were applied. Indapamide/amlodipine SPC cost is 
based on average pharmacy prices reported in April 2014 (18.13PLN and 19.75PLN 
respectively for 1.5+5mg and 1.5+10mg /30 tabs); 30% patient copayment was 
assumed. Cost of FC was calculated as an average cost of reimbursed indapamide 
and amlodipine products in corresponding doses. All costs present 2014 values, 
and are expressed in Polish zloty (PLN). Costs and effects were discounted with 
5% and 3.5% rates. Results: Indapamide/amlodipine SPC compared with FC gen-
erates additional life years (LYs) and quality adjusted life years (QALYs), and is 
highly cost-effective from public payer perspective and dominant from patient 
perspective. Difference between SPC and FC in LYs and QALYs was: 0.007960 and 
0.020809. Difference in total costs from public payer perspective and from patient 
perspective was 113.14PLN (27.07EUR) and -211.31PLN (-50.56 EUR). ICUR from 
public payer perspective was 5,437PLN/QALY (1,301EUR/QALY). At prices +199% vs 
the base-case, SPC remains a cost-effective technology from public payer perspec-
tive according to the legally defined CE threshold (111,381PLN/QALY= 26,653EUR/
QALY). At prices -9.9% vs base-case, SPC is a dominant/cost saving technology vs 
the FC comparator. ConClusions: From public payer perspective, indapamide/
amlodipine SPC compared with FC is a highly cost-effective treatment option for 
hypertensive patients in contemporary Polish setting. From patient perspective, 
SPC is a dominant technology.
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objeCtives: Numerous trials have shown that lowering LDL cholesterol (LDL-C) 
reduces CVD events; however, at any LDL-C level, residual risk remains. LDL parti-
cle concentration (LDL-P) may be a better predictor of events, but no studies have 
evaluated its cost-effectiveness. We used the Archimedes model to evaluate the 
cost-effectiveness of using LDL-C or LDL-P in preventing cardiovascular disease 
in dyslipidemic patients. Methods: Archimedes is a highly detailed, large-scale 
simulation model of physiology, disease and health care systems. We created a 
simulated population of 1,000,000 individuals age 20-84 reflective of real subjects 
in the NHANES dataset. Because NHANES does not contain LDL-P values, they 
were imputed maintaining covariance with other biomarkers. The study had three 
arms: •Control: subjects evaluated for therapy for elevated LDL-C and treated 
with statins to LDL-C goals outlined in ATP-III; •LDL-P Alone: subjects evaluated 
and treated based solely on their LDL-P values; •Dual Arm: subjects evaluated 
